Scholarlink

Purpose <p>Alterations in bone metabolism are common in chronic liver disease. This study aimed to assess the risk of fragility fractures in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes (T2D), using the trabecular bone score (TBS) as a marker of bone quality.</p> Methods <p>Patients with MASLD and T2D were consecutively enrolled at the Medicine and Hepatology Unit of the University Hospital of Messina between February and October 2024. Exclusion criteria included decompensated cirrhosis, secondary osteoporosis, and long-term use of bone-active therapies. All participants underwent liver elastography for steatosis and fibrosis assessment, with the Controlled Attenuation Parameter (CAP) used to quantify hepatic fat content, and dual-energy X-ray absorptiometry with TBS and vertebral fracture assessment.</p> Results <p>One hundred-five patients (56 males; median age 62&#xa0;years) were included in the study. Vertebral fractures were detected in 54 patients (51.4%), of whom 45 (83.3%) had pathological TBS (&lt; 1.350) despite normal bone mineral density. Regression analysis confirmed a strong association between pathological TBS and fracture risk (p &lt; 0.001). Pathological TBS was also significantly associated with body mass index &gt; 30&#xa0;kg/m<sup>2</sup> (p &lt; 0.001), CAP ≥ 248&#xa0;dB/m (p = 0.034), and male sex (p = 0.002), but not with advanced liver fibrosis.</p> Conclusion <p>Bone fragility represents a relevant comorbidity in patients with MASLD and T2D, independent of fibrosis severity. TBS appears to be a sensitive marker of skeletal fragility, while CAP may help identify patients at increased risk of fracture.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Trabecular bone score enhances fracture risk stratification in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus

  • 期刊论文

  • 发表日期：

    2026年3月12日

查看全文
  • Clelia Asero,
  • Cecilia Oliveri,
  • Maria Stella Franzè,
  • Adele Di Giovanni,
  • Roberto Filomia,
  • Gaia Caccamo,
  • Concetta Pitrone,
  • Carlo Saitta,
  • Carmela Morace,
  • Nunziata Morabito,
  • Giorgio Basile,
  • Antonino Catalano,
  • Irene Cacciola

摘要

Purpose

Alterations in bone metabolism are common in chronic liver disease. This study aimed to assess the risk of fragility fractures in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) and type 2 diabetes (T2D), using the trabecular bone score (TBS) as a marker of bone quality.

Methods

Patients with MASLD and T2D were consecutively enrolled at the Medicine and Hepatology Unit of the University Hospital of Messina between February and October 2024. Exclusion criteria included decompensated cirrhosis, secondary osteoporosis, and long-term use of bone-active therapies. All participants underwent liver elastography for steatosis and fibrosis assessment, with the Controlled Attenuation Parameter (CAP) used to quantify hepatic fat content, and dual-energy X-ray absorptiometry with TBS and vertebral fracture assessment.

Results

One hundred-five patients (56 males; median age 62 years) were included in the study. Vertebral fractures were detected in 54 patients (51.4%), of whom 45 (83.3%) had pathological TBS (< 1.350) despite normal bone mineral density. Regression analysis confirmed a strong association between pathological TBS and fracture risk (p < 0.001). Pathological TBS was also significantly associated with body mass index > 30 kg/m2 (p < 0.001), CAP ≥ 248 dB/m (p = 0.034), and male sex (p = 0.002), but not with advanced liver fibrosis.

Conclusion

Bone fragility represents a relevant comorbidity in patients with MASLD and T2D, independent of fibrosis severity. TBS appears to be a sensitive marker of skeletal fragility, while CAP may help identify patients at increased risk of fracture.